Analysts Raise Edwards Lifesciences FY2025 Earnings Forecast

Investment analysts at Zacks Research have revised their earnings per share (EPS) estimates for **Edwards Lifesciences Corporation** for the fiscal year 2025. In a report released on **November 18, 2023**, Zacks now projects that the medical technology company will achieve an EPS of **$2.58**, a notable increase from their previous estimate of **$2.49**. This adjustment comes as the consensus estimate for the company’s current full-year earnings stands at **$2.45** per share.

In addition to the FY2025 forecast, Zacks Research has provided estimates for upcoming quarterly earnings. The analysts anticipate **$0.60** EPS for the fourth quarter of 2025, and they expect earnings for the first, second, and third quarters of 2026 to reach **$0.66**, **$0.71**, and **$0.71**, respectively. For the fourth quarter of 2026, the projected EPS is **$0.73**, with an overall FY2026 estimate of **$2.81** EPS. Looking further ahead, the estimates suggest **$0.78** EPS for both the first and second quarters of 2027, culminating in a projected FY2027 EPS of **$3.15**.

Edwards Lifesciences reported its most recent quarterly earnings on **October 30, 2023**. The company posted an EPS of **$0.67**, exceeding the consensus estimate of **$0.59** by **$0.08**. The revenue for the quarter reached **$1.55 billion**, surpassing analyst expectations of **$1.49 billion**. This performance reflects a robust return on equity of **15.01%** and a remarkable net margin of **72.96%**, with quarterly revenue up **14.7%** compared to the same period last year.

Stock Performance and Insider Activity

Following these developments, shares of **Edwards Lifesciences** opened at **$84.13** on **November 19, 2023**. The stock has a market capitalization of **$48.82 billion**, a price-to-earnings (P/E) ratio of **12.11**, and a price-to-earnings-growth (PEG) ratio of **3.97**. The company’s beta stands at **1.03**, indicating a moderate level of volatility compared to the market. With a debt-to-equity ratio of **0.06**, the company demonstrates strong financial health, supported by a current ratio of **4.68** and a quick ratio of **3.87**. The stock has fluctuated significantly over the past year, with a low of **$65.94** and a high of **$87.21**.

In related news, **Daniel J. Lippis**, Vice President at Edwards Lifesciences, sold **1,020** shares of the company’s stock on **November 10, 2023**, at an average price of **$82.55**, totaling **$84,201.00**. Following this transaction, Lippis holds **22,002** shares valued at approximately **$1,816,265.10**, reflecting a **4.43%** decrease in his position. The transaction was officially disclosed to the **Securities and Exchange Commission (SEC)**.

Additionally, **Scott B. Ullem**, Chief Financial Officer, sold **13,000** shares on the same day at an average price of **$83.08**, amounting to **$1,080,040.00**. Ullem’s remaining shares total **39,898**, valued at about **$3,314,725.84**, representing a **24.58%** reduction in his stake.

Institutional Investor Movements

Recent activity from institutional investors indicates a significant interest in Edwards Lifesciences. Several hedge funds have either increased or established new positions in the company. Notably, **JPL Wealth Management LLC** acquired a new stake valued at approximately **$25,000** during the third quarter. Similarly, **Quantbot Technologies LP** and **SouthState Corp** made new investments valued at approximately **$26,000** and **$27,000**, respectively.

In the second quarter, **Rosenberg Matthew Hamilton** also acquired a new position worth **$28,000**. Additionally, **True Wealth Design LLC** expanded its holdings in Edwards Lifesciences by **251.5%** in the third quarter, now owning **362** shares valued at around **$28,000** after purchasing an additional **259** shares.

Overall, institutional investors and hedge funds now control **79.46%** of Edwards Lifesciences’ stock, reflecting strong institutional confidence in the company’s future prospects.

Edwards Lifesciences Corporation specializes in products and technologies for structural heart disease and critical care monitoring, operating across the United States, Europe, Japan, and other international markets. Its offerings include innovative transcatheter heart valve replacement systems and repair products for various heart valve ailments.